Ryan Sullivan, MD, associate professor, Medicine, Harvard Medical School and associate professor, Hematology/Oncology, Massachusetts General Hospital, explains how tumor infiltrating lymphocytes (TIL) could impact the melanoma treatment landscape if approved by the FDA.
Video Reports
Novel bispecific T-cell receptor therapy shows early promise in advanced solid tumors
An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.
Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma
Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair, Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, member, Charles Perkins Centre, discusses evaluating pembrolizumab (Keytruda) vs placebo in stage IIB or IIC melanoma.
Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma
Mario Sznol, MD, a professor of Medicine (Medical Oncology) and the co-leader of Cancer Immunology at Yale Cancer Center, and the co-director of Yale SPORE in Skin Cancer, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.